Design and optimisation of novel MEK inhibitors for the management of neoplastic disease using the tak-733 scaffold as a lead molecule
- At: Seville (Spain) (2022)
- Type: Poster
- Poster code: APS-079
- By: SHOEMAKE, Claire ()
- Co-author(s): Mr Roderick Micallef, Pharmacy
Dr Claire Shoemake, Senior Lecturer
The mitogen-activated protein kinase signalling pathway is dysregulated in numerous human malignancies. Mutations exert their oncogenic activity through downstream proteins such as the MEK1/2 protein kinases. MEK inhibitors have been approved for clinical use in the treatment of BRAF-mutated melanoma, and are undergoing clinical trials for the.. The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.